

ERS Research Seminar

**Pharmacology of asthma and COPD: current and future
developments**

10 – 11 June 2021; Napoli, Italy

Day 1 – Thursday, 10 June 2020

08:45-09:00 Registration
09:00-09:10 Welcome and introduction

Session 1: Pharmacology of asthma and COPD - current knowledge

Chairs: Dave Singh and Joergen Vestbo

09:10-09:30 Understanding the mechanism of action of bronchodilators in asthma and COPD
(*Maria Gabriella Matera – IT*)
09:30-09:40 Discussion
09:40-10:00 How do inhaled steroids work and interact in asthma and COPD? (*Maarten Van Den Berge – NL*)
10:00-10:10 Discussion
10:10-10:30 Biomarker guided pharmacological intervention (*Daiana Stolz – CH*)
10:30-10:40 Discussion
10:40-11:10 General discussion
11:10-11:30 *Coffee break*

Session 2: Challenges for clinical development

Chairs: Clive Page and Alberto Papi

11:30-12:00 Key challenges faced during clinical development of anti-inflammatory drugs for
asthma and COPD
12:00-12:30 General discussion
12:30-13:30 *Lunch*

Session 3: Emerging new concepts and treatments

Chairs: Maria Belvisi and Mario Cazzola

13:30-13:50 Do we understand remodeling in asthma and COPD? (*Eleni Papakonstantinou – GR*)
13:50-14:00 Discussion
14:00-14:20 Lung regeneration: is it still far from reality? (*Reinoud Gosens – NL*)
14:20-14:30 Discussion
14:30-14:50 Emerging classes of drugs for the treatment of obstructive lung disease (*Chris
Brightling – UK*)
14:50-15:00 Discussion

15:00-17:30 Session 4 – Breakout: what is this seminar’s position on the selection of treatment in asthma and COPD? – Dave Singh and Paola Rogliani

15:00-15:15 Explain tasks and operating methods

15:30-16:15 Session 1 - Identifying surrogate markers and outcomes – Dave Singh

- Which surrogate markers can be used to assess and quantify disease in a pre-clinical stage? Do we need drug intervention in pre-clinical detectable disease?
- Which are the read-outs to assess drug effect in the progression of the disease?
- Is an effect on remodeling required for drug efficacy? If so, how to assess it?

16:15-17:00 Session 2 - How do we select treatments for patients with severe asthma and COPD? – Paola Rogliani

- What is non-clinical evidence to sustain combination therapy including ICS in COPD? What about LABA/LAMA in asthma?
- Are there realistic treatment goals for monoclonal antibodies in COPD? How do they differ from asthma?
- Which features suggest considering patients for non-pharmacological, i.e. bronchoscopic interventions in asthma and COPD?

17:00-17:30 Round table

Day 2 – Friday, 11 June 2020

09:00-09:30 Summary of day 1 and possible output, next steps and plenary discussion

Session 5: Challenges in the treatment of patient with asthma and COPD

Chairs: Maarten Van Den Berge and Clive Page

09:30-09:50 New insights into steroid resistance (*Maria Belvisi – SE*)

09:50-10:00 Discussion

10:00-10:20 Comorbidities and drug interactions (*Mario Cazzola – IT*)

10:20-10:30 Discussion

10:30-10:50 Pharmacogenetics of asthma and COPD and treatment (*Anke-Hilse Maitland- Van Der Zee – NL*)

10:50-11:00 Discussion

11:00-11:20 General discussion

11:20-11:40 Coffee break

- 11:40-12:20** **Session 6 – Breakout: what is this seminar’s position on the selection of treatment in asthma and COPD? – Joergen Vestbo**
- 11:40-11:50 Explain tasks and operating methods
- 11:50-12:20 **Session 1 - How to streamline clinical and basic research**
- How to translate relevant clinical questions to experiments?
 - How to translate experimental data to clinical practice?
 - Which themes should be prioritized?
 - How can academia and industry cooperate?
- 12:20-12:50 *Round table*
- 12:50-13:00 Conclusion
- 13:00-14:00 *Lunch and Departure*